{"id":295527,"date":"2025-06-09T00:00:00","date_gmt":"2025-06-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0001-2024-biopharma-hospital-treated-gram-negative-infections-current-treatment-current\/"},"modified":"2026-04-28T11:11:36","modified_gmt":"2026-04-28T11:11:36","slug":"cutrid0001-2025-biopharma-hospital-treated-gram-negative-infections-current-treatment-current-treatment-physician","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0001-2025-biopharma-hospital-treated-gram-negative-infections-current-treatment-current-treatment-physician\/","title":{"rendered":"Hospital-Treated Gram-Negative Infections &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Hospital-Treated Gram-Negative Infections (US)"},"content":{"rendered":"<p>Most inpatients with hospital-treated gram-negative infections (<abbr data-abbreviation-entity=\"4827\" title=\"gram-negative infection\">GNI<\/abbr>s) are successfully treated empirically with generic antibiotics. These agents continue to dominate the hospital-treated <abbr data-abbreviation-entity=\"4827\" title=\"gram-negative infection\">GNI<\/abbr> market, thus branded products like Allergan \/ AbbVie\u2019s Avycaz, Shionogi\u2019s Fetroja, Merck &#038; Co.\u2019s Recarbrio, Innoviva \/ Entasis\u2019s Xacduro, Tetraphase Pharmaceuticals\u2019 Xerava, and Merck &#038; Co.\u2019s Zerbaxa are typically restricted to later lines of therapy. The rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant <abbr data-abbreviation-entity=\"4827\" title=\"gram-negative infection\">GNI<\/abbr>s. In this analysis, we explore brand use in this market based on factors such as activity against key drug-resistant pathogens. Furthermore, hospital-based <abbr data-abbreviation-entity=\"4827\" title=\"gram-negative infection\">GNI<\/abbr> specialists offer insight into how they treat <abbr data-abbreviation-entity=\"4827\" title=\"gram-negative infection\">GNI<\/abbr>s in response to growing drug resistance. <i> <\/i><\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which first-, second-, and third-line therapies are prescribed for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?<\/li>\n<li>How are physicians approaching the treatment of infections caused by drug-resistant pathogens?<\/li>\n<li>Which factors, both clinical and nonclinical, drive, and limit, the prescribing of branded agents such as Recarbrio, Fetroja, Xerava, and Xacduro?<\/li>\n<li>What will drive use of relatively new therapies, and in which infection types will they be used? Which current agents will be most affected?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><b>Publication date:\u00a0<\/b>June 2025<\/p>\n<p><b>Geography:\u00a0<\/b>United States<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 100 U.S. hospital-based, infectious disease and critical care specialists<\/p>\n<p><strong>Key drugs covered:\u00a0<\/strong>Avycaz, Fetroja, Recarbrio, Xacduro, Xerava, Zerbaxa<\/p>\n<p><strong>Key analyses:\u00a0<\/strong>Factors influencing disease management and treatment decisions; drivers and constraints of treatment selection<b>; <\/b>physician-reported treatment practices and brand-level patient shares; physician-reported antibiotic use by indication; physician-reported recent \/ anticipated changes in brand usage or treatment approach<\/p>\n","protected":false},"template":"","class_list":["post-295527","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295527\/revisions"}],"predecessor-version":[{"id":575779,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295527\/revisions\/575779"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}